Valinomycin separation and purification method
Through petroleum ether extraction and column chromatography gradient elution, combined with the use of organic solvents such as methanol and ethanol, the problem of low yield and purity during the separation and purification of valimycin is solved, and high-efficiency valimycin is achieved Mass production and improve the sustainability of the process through solvent recovery and environmentally friendly treatment.
Patent Information
- Application Number
- CN202411263265.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-10
- Publication Date
- 2024-12-06
AI Technical Summary
In the prior art, the yield and purity of valimycin are low during the separation and purification process, and are not suitable for industrial production. There is a lack of experimental plans for mass production, and it is difficult to achieve green and sustainable development by recycling the organic solvents used.
Using petroleum ether extraction, column chromatography gradient elution and crystallization drying, gradient elution is performed by adjusting the ratio of petroleum ether and acetone, combined with the use of organic solvents such as methanol and ethanol, the efficient separation and purification of valimycin is achieved. , reduces dependence on HPLC, simplifies process steps and improves yield and purity.
High yields (61%) and high purity (95.01%) of valimycin are achieved, process steps are simplified, cost reduction, and process sustainability is improved through solvent recovery and environmentally friendly treatment.
Smart Images

Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
Description
Technical Field
[0001] The invention relates to the field of microbial fermentation, and in particular to a method for separating and purifying valinomycin. Background Art
[0002] Valinomycin is a nonribosomal peptide compound first isolated from Streptomyces fulvissimus It is a neutral, fat-soluble antibiotic. The molecular formula of valinomycin is C 54 H 90 N6O 18 , is a zwitterionic substance, and its structure is shown in the following formula.
[0003]
[0004] Valinomycin is a cyclic depsipeptide composed of alternating peptide and ester bonds between each residue. This structural conformation forms a hydrophobic surface and a polar cavity in which a potassium ion (K + ) can coordinate with the six oxygen atoms of the internal ester carbonyl group to form valinomycin-K + The cavity is sized to accommodate K + However, it is not suitable for accommodating other metal ions, making valinomycin a potassium-specific ion carrier.
[0005] Valinomycin has antifungal, antiviral, insecticidal and antitumor effects. In recent studies, valinomycin, as a mitochondrial autophagy activator, also plays a positive role in the treatment of Parkinson's disease and Alzheimer's disease. Valinomycin is insoluble in water, but soluble in organic solvents such as methanol, ethanol, chloroform, acetone, petroleum ether, and ethyl acetate. The reported separation and purification of valinomycin is through HPLC separation on a semi-preparative column, and only trace samples can be obtained. There is currently no experimental plan to directly crystallize valinomycin for mass production.
[0006] Therefore, it is necessary to provide a crystallization process for separating and purifying valinomycin, which can ensure that valinomycin has a high yield and purity while carrying out batch production. In addition, part of the organic solvent used in the process is recovered and reused to ensure the green and sustainable development of the process route. Summary of the invention
[0007] In order to solve the problem that the yield and purity of valinomycin separated and purified in the prior art are both low and not suitable for use in industrial production processes, the present invention provides a crystallization process for separating and purifying valinomycin, which can ensure that valinomycin has a high yield and purity while carrying out batch production.
[0008] A method for separating and purifying valinomycin, comprising: (S.1) centrifuging the fermentation liquid containing valinomycin to remove the supernatant to obtain mycelium, extracting the mycelium with an organic solvent, and concentrating the extract; (S.2) extracting the extract with petroleum ether, washing with water, and after demulsification, collecting the petroleum ether phase and concentrating it by rotary evaporation to obtain a crude extract; (S.3) using column chromatography to gradient elute the crude petroleum ether extract according to polarity using eluents of different proportions, and concentrating under reduced pressure; (S.4) Using an organic solvent for crystallization, collecting, and drying to obtain valinomycin.
[0009] The present invention screens and uses petroleum ether to extract the fermentation broth, and utilizes the fat-soluble characteristics of valinomycin to effectively separate and enrich the target product. This method has higher selectivity and efficiency than traditional solvents. It is no longer necessary to accurately separate and purify valinomycin by HPLC. The efficient separation and purity improvement of valinomycin can be achieved by silica gel column chromatography. The steps of extraction, washing, demulsification and rotary evaporation concentration are relatively simple and easy to implement in laboratories or industrial production. These steps usually do not require complex equipment and operating skills, and are convenient for large-scale application. Solvents such as petroleum ether are relatively cheap and easy to obtain, which reduces the cost of experiments or production. The rotary evaporation concentration method can recycle solvents, further reducing costs. Waste gas, waste liquid, etc. generated during the rotary evaporation concentration process can meet environmental emission standards through appropriate treatment. The separation and purification method, after column chromatography and crystallization drying, obtains white valinomycin crystals with a recovery rate of 61% and a purity of 95.01%.
[0010] Preferably, the organic solvent used for the concentration and purification in (S.1) is one or more of methanol and ethanol.
[0011] Methanol has good solubility for many organic substances, especially for some highly polar compounds. Valinomycin is mainly fat-soluble, and its polar part may also interact with methanol, thus facilitating its dissolution and extraction. Compared with some other organic solvents, methanol is more economical and widely available, making it convenient for large-scale production and application.
[0012] Preferably, (S.2) the demulsification is carried out by washing with saturated sodium chloride water or by centrifugal demulsification.
[0013] Saturated sodium chloride washing During the washing process, the use of saturated sodium chloride solution can more effectively remove water-soluble impurities while reducing the loss of the target product. Centrifugal demulsification is suitable for many types of emulsion systems, including complex emulsions containing surfactants and fats. It is not affected by the properties of the components in the emulsion and can stably achieve demulsification effects.
[0014] Preferably, (S.3) the eluent is a mixture of petroleum ether and acetone.
[0015] Petroleum ether and acetone are non-polar solvents that have good solubility for non-polar or weakly polar compounds. As a fat-soluble antibiotic, valinomycin contains more non-polar groups in its molecular structure, so it is easily dissolved by non-polar solvents such as petroleum ether and acetone. Petroleum ether has moderate volatility, which is convenient for subsequent treatment during the extraction process. At the same time, petroleum ether is relatively safe during use, reducing operational risks.
[0016] Preferably, the ratio of the eluent in (S.3) is petroleum ether:acetone=100:(0-20).
[0017] For the gradient elution process, pure petroleum ether or nearly pure petroleum ether is used as the eluent at the beginning. As the elution proceeds, the proportion of acetone is gradually increased to enhance the polarity of the eluent. This method helps to elute compounds of different polarities one by one and improve the separation effect. By adjusting the ratio of petroleum ether and acetone, the separation process can be optimized. For some complex mixtures, it may be necessary to determine the best eluent ratio through multiple experiments to obtain the best separation effect. In some cases, the mixture may contain some impurities with strong polarity. By gradually increasing the proportion of acetone, these impurities can be eluted more effectively and their interference with the purity of the target compound can be reduced.
[0018] Preferably, the eluent volume is 0.5-2 BV.
[0019] For compounds that bind weakly to the stationary phase, a smaller eluent volume is used. However, for some high-purity separation requirements, too little eluent volume may result in incomplete separation or low yield. When a larger eluent volume is used, most or even all of the target compounds can be eluted from the silica gel column, and some non-target compounds (such as impurities) may also be eluted together. However, too much eluent volume will increase the consumption of solvent and the difficulty of subsequent processing, and may also reduce the concentration of the purified product. Therefore, different elution volumes are selected according to different situations.
[0020] Preferably, the gradient elution described in (S.3) obtains 7 components with increasing polarity.
[0021] By adjusting the flow rate and solvent ratio, several components with different polarities were obtained. Gradient elution can obtain 7 components with increasing polarity. It has many advantages, such as high efficiency, high separation, short analysis cycle, good peak shape, high sensitivity, high flexibility, good reproducibility, and suitability for complex samples. These advantages make gradient elution widely used in the field of column chromatography separation.
[0022] Preferably, (S.4) the three components with greater polarity are concentrated under reduced pressure.
[0023] The three components with higher polarity can be concentrated under reduced pressure to improve the concentration efficiency, protect the stability of the components and facilitate subsequent processing. Through reduced pressure concentration, the components can be concentrated at a lower temperature, thus avoiding the decomposition or deterioration of the components that may be caused by high temperature. Under reduced pressure conditions, the vapor pressure on the liquid surface is reduced, which speeds up the evaporation rate. This helps to evaporate a large amount of solvent in a short time and improve the concentration efficiency.
[0024] Preferably, the organic solvent used in (S.4) is one or more of methanol, ethanol and n-butyl ether.
[0025] Methanol and ethanol are alcohol solvents, and methanol and ethanol have a certain solubility for valinomycin. This enables them to effectively precipitate valinomycin during the cooling crystallization process, thereby obtaining high-purity valinomycin crystals. n-Butyl ether, as an ether solvent, also has a certain solubility for valinomycin. Although its solubility is not as strong as that of methanol and ethanol, under certain conditions, n-butyl ether may be used as an auxiliary solvent or a preferred solvent under specific conditions to effectively precipitate valinomycin during the cooling crystallization process, thereby obtaining high-purity valinomycin crystals. Methanol, ethanol, and n-butyl ether are selected as solvents, which have good solubility, relatively low cost, certain safety, and environmental protection for valinomycin.
[0026] Preferably, in the crystallization process (S.4), heating in a 50°C water bath and gradient cooling are used to obtain high-purity valinomycin.
[0027] After heating to a certain degree, the gradual crystallization of valinomycin can be promoted by gradient cooling. It helps to form a uniform and dense crystal structure, reduce the inclusion and co-precipitation of impurities, and thus improve the purity of the product. The use of 50°C water bath heating and gradient cooling to obtain high-purity valinomycin is based on comprehensive consideration and optimization of temperature, solvent, operation control, and subsequent treatment. This method can effectively control the crystallization process, reduce the generation and accumulation of impurities, and thus obtain high-quality valinomycin products.
[0028] The present invention has the following beneficial effects: (1) The present invention uses column chromatography to separate and purify valinomycin, which has a simple process and the used methanol, ethanol and petroleum ether solvents can be recycled. It is green and environmentally friendly, saves costs and is suitable for mass production.
[0029] (2) The method of the present invention does not require the use of semi-preparative chromatography to separate by HPLC during the sample acquisition stage. Instead, the method uses an organic solvent crystallization method, which greatly increases the amount of valinomycin sample and allows for batch production. In addition, the valinomycin crystallized by this method has a high yield and high purity. BRIEF DESCRIPTION OF THE DRAWINGS
[0030] Figure 1 HPLC for the separation and purification of valinomycin.
[0031] Figure 2 For the separation and purification of valinomycin 1 H-NMR.
[0032] Figure 3 For the separation and purification of valinomycin 13 C-NMR.
[0033] Figure 4 High-resolution mass spectrometry for the separation and purification of valinomycin.
[0034] Figure 5 This is the infrared absorption spectrum of the isolated and purified valinomycin. DETAILED DESCRIPTION
[0035] The following is an explanation of the embodiments of the present invention by specific specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied by other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention. It should be noted that, in the absence of conflict, the features in the following embodiments and embodiments can be combined with each other. In the embodiments of the present invention, the methods used are all conventional methods unless otherwise specified, and the reagents used can be obtained from commercial sources.
[0036] [Valinomycin fermentation]: Streptomyces sp. IFE-v1m38 was inoculated into a 500 mL Erlenmeyer flask containing 50 mL of liquid seed culture medium (10.0 g / L yeast extract, 5.0 g / L beef extract, 2.0 g / L NaCl, 0.5 g / L MgSO4·7H2O, 0.5 g / L K2HPO4·3H2O), and cultured at 28°C and 200 rpm for 24 h to obtain a seed solution. The bacterial liquid was inoculated at an inoculum rate of 6% into a 5L fermentation tank containing 3L of fermentation medium (20.0g / L soybean cake powder, 10.0g / L soluble starch (gelatinized in a boiling water bath), 20g / L glucose, 4.0g / L tryptone, 5.0g / L yeast extract, 3.0g / L beef extract, 2.0g / L NaCl, 0.5g / L MgSO4·7H2O, 0.5g / L K2HPO4·3H2O, 3.0g / L CaCO3, 0.01g / L FeSO4·7H2O, 1.5‰ defoaming agent), and the fermentation culture was carried out for 168h at a temperature of 28°C, a stirring paddle speed of 350rpm, a ventilation volume of 3.0vvm, and ammonia water to maintain pH=7.0 to obtain a fermentation liquid. The fermentation liquid was centrifuged and the supernatant was discarded. The mycelium was soaked in ethanol solution for 2 to 3 times. The ethanol soaking liquid was concentrated by rotary evaporation and allowed to stand.
[0037] [Selection of extraction agent]: Take 0.1 g of the concentrate and dissolve it in 1 ml of toluene, glacial acetic acid, ether, chloroform, petroleum ether, and acetone respectively. Use HPLC to detect the content of valinomycin therein. The results are shown in Table 1: Table 1. Valinomycin content in different organic solvents Solvents Phenomenon Valinomycin content in concentrated samples Toluene Large amount of dissolution 299.8 mg / L glacial acetic acid Solution crystallization 116.4 mg / L Ether The solution evaporated completely —— Chloroform All dissolved 156 mg / L Petroleum ether Large amount of dissolution 44.9 mg / L acetone Large amount of dissolution 116 mg / L In glacial acetic acid, the solution crystallized into an icy solid and was not suitable for further experiments. Ether was volatile and was not suitable for further experiments. Chloroform dissolved all the samples and contained many impurities and was not suitable for further experiments. The selected toluene, petroleum ether and acetone were further verified.
[0038] Take 0.5 g of valinomycin concentrate and dissolve it in 1 ml of acetone. The concentration of valinomycin detected by liquid phase is 1.05 g / L. After nitrogen blowing, 1 ml of acetone is re-dissolved. The concentration of valinomycin detected by liquid phase is 0.14 g / L. Take 0.5 g of valinomycin concentrate and dissolve it in 1 ml of petroleum ether. The concentration of valinomycin detected by liquid phase is 0.85 g / L. After nitrogen blowing, 1 ml of petroleum ether is re-dissolved. The concentration of valinomycin detected by liquid phase is 0.18 g / L. The insoluble matter in the petroleum ether solution is re-dissolved in acetone and the liquid phase detection does not contain valinomycin. Take 0.5 g of valinomycin concentrate and dissolve it in 1 ml of toluene. The concentration of valinomycin detected by liquid phase is 0.74 g / L. After nitrogen blowing, 1 ml of toluene is re-dissolved. The concentration of valinomycin detected by liquid phase is 0.23 g / L. According to the experimental results, petroleum ether has the best extraction effect on valinomycin in the concentrate.
[0039] [Water washing, demulsification, collection of crude extract]: The fermentation liquid was centrifuged and the supernatant was discarded. The mycelium was soaked in ethanol solution for 2-3 times. The ethanol soaking liquid was concentrated by rotary evaporation and allowed to stand. 1.5 volumes of petroleum ether were used to re-dissolve and extract valinomycin, and the insoluble matter was removed. 1 volume of saturated sodium chloride solution was used to extract twice to remove water-soluble impurities, and the supernatant was taken. The emulsion layer was centrifuged at 4200 r for 3 min to break the emulsion, and the supernatant was taken again. The supernatant was rotary evaporated again to obtain a greasy substance and a valinomycin sample with water-soluble impurities removed.
[0040] [Select eluent according to solvent polarity]: Six eluents, pure methanol, pure chloroform, pure petroleum ether, pure acetone, chloroform: methanol = 100:1, petroleum ether: acetone = 100:1, were used. The sample point, Rf = 1, could be observed at the top of the thin layer chromatography plate of pure methanol, pure acetone, and chloroform: methanol = 100:1. The sample point could be observed at Rf = 0.1 in petroleum ether: acetone = 100:1. The Rf of pure chloroform and pure petroleum ether was 0. The chloroform / methanol system had a poor separation and development effect on valinomycin, and the petroleum ether / acetone system was further explored in the future.
[0041] [Select eluent ratio]: Petroleum ether / acetone system (add 100 μL of glacial acetic acid if there is some tailing): In the system of petroleum ether:acetone = 100:0, no sample point appeared on the TLC plate. The experiment was gradually carried out with petroleum ether:acetone = 100:0~100:20. When petroleum ether:acetone = 100:1, the Rf of the valinomycin sample on the TLC plate was 0.1. When petroleum ether:acetone = 100:6, the Rf of the valinomycin sample on the TLC plate was 0.2. When petroleum ether:acetone = 100:10, the Rf of the valinomycin sample on the TLC plate was 0.35. When petroleum ether:acetone = 100:20, the Rf of the valinomycin sample on the TLC plate was 0.5. When petroleum ether:acetone = 100:40, the Rf of the valinomycin sample on the TLC plate was 0.75.
[0042] According to the results of thin layer chromatography analysis, petroleum ether / acetone system was selected as the eluent for the subsequent silica gel column.
[0043] [Column chromatography gradient elution, reduced pressure concentration]: Take a 60*600 mm / 24 chromatography column, load 1 L of silica gel powder, and use petroleum ether nitrogen blowing method to install the column. The silica gel column swells overnight, and 100 ml of crude valinomycin extract is added to the upper layer of silica gel, and a layer of quartz sand is added to seal. Use petroleum ether: acetone = 100:0~100:20 to wash 1BV respectively. The elution flow rate is 1BV / 2h, and the eluate is collected in a 250 ml conical flask. After nitrogen blowing, the collected eluate is re-dissolved in liquid methanol and detected by thin layer chromatography and high performance liquid chromatography ( Figure 1 ), enrich the fraction with high valinomycin content. {The retention time is 30.399, which is the peak of valinomycin.} The loading concentration is 10 g / L, and the liquid phase detection shows that the enriched fraction contains 0.7 g valinomycin. The fraction with high valinomycin content is evaporated and concentrated at 50°C using a rotary evaporator until no liquid flows out of the condenser tube, obtaining a yellow flaky solid.
[0044] The petroleum ether acetone mixture obtained by rotary evaporation of all the effluent is washed 3 to 5 times with deionized water, and the upper layer of petroleum ether can be recycled as the eluent of silica gel column chromatography.
[0045] [Crystallization, collection, and drying of valinomycin]: A certain amount of n-butyl ether was added to the obtained yellow flaky solid, heated in a 50 °C water bath with stirring for 1 h, and then gradually cooled (1 °C every 10 min) and cooled in a water bath to room temperature. The solid was stored in an ice water bath for 1 h, and a large amount of crystals were observed to precipitate. White crystals were obtained by filtration under reduced pressure and dried in a vacuum oven at 45 °C for 24 h to obtain 0.61 g of white valinomycin crystals with a yield of 61%. The purity was 95.01% as determined by HPLC.
[0046] The structure of the purified valinomycin crystals was identified according to 1 H-NMR( Figure 2 ) and 13 C-NMR ( Figure 3 )、High resolution mass spectrometry( Figure 4 )、Infrared absorption spectrum( Figure 5 ) The results showed that the obtained crystals were valinomycin.
[0047] The data of each test are as follows: 1 H NMR (400 MHz, Chloroform- d ) δ 7.87 (d, J = 8.0 Hz, 3H), 7.79 (d, J =6.2 Hz, 3H), 5.33 (q, J = 6.7 Hz, 3H), 5.01 (d, J = 3.1 Hz, 3H), 4.11 (dd, J = 9.8,8.1 Hz, 3H), 3.97 (dd, J = 10.1, 6.2 Hz, 3H), 2.36 (d, J = 6.6 Hz, 3H), 2.31 (dd, J = 8.8, 5.3 Hz, 3H), 2.27 – 2.17 (m, 3H), 1.44 (d, J = 6.8 Hz, 9H), 1.19 – 1.03(m, 18H), 1.03 – 0.96 (m, 18H), 0.94 (d, J = 3.7 Hz, 18H). 13 C NMR (101 MHz, Chloroform- d ) δ 172.67, 171.94, 170.92, 170.19,78.66, 70.32, 60.57, 59.04, 30.34, 28.50 (d, J = 10.7 Hz), 19.80, 19.60 (d, J =2.5 Hz), 19.25 (d, J = 4.8 Hz), 17.22, 16.74. By HRESIMS spectrum, m / z=1128.6672[M+NH4+ ],m / z= 1133.6183[M+Na + ], molecular weight of the compound: 1111.32, molecular formula of the compound: C 54 H 90 N6O 18 .
[0048] Analyze the functional groups contained in the substance according to the infrared results IR (KBr) vmax cm-1 : 3405 cm -1 and 3311 cm -1 (NH stretching vibration), 2965cm -1 (CH stretching vibration on saturated atoms), 1762 cm -1 and 1742 cm -1 (C=O of ester bond), 1679 cm -1 and 1652 cm -1 (Amide I band, stretching vibration absorption peak of C=O bond of O=C-NH), 1538 cm -1 (CN telescopic), and 1181 cm -1 (The carbon-carbon skeleton vibrates, containing -CH-(CH3)2).
Claims
1. A method for separating and purifying valinomycin, characterized in that: The method comprises: (S.1) centrifuging the fermentation liquid containing valinomycin to remove the supernatant to obtain mycelium, extracting the mycelium with an organic solvent, and concentrating the extract; (S.2) extracting the extract with petroleum ether, washing with water, and after demulsification, collecting the petroleum ether phase and concentrating it by rotary evaporation to obtain a crude extract; (S.3) using column chromatography to gradient elute the crude petroleum ether extract according to polarity using eluents of different proportions, and concentrating under reduced pressure; (S.4) Using an organic solvent for crystallization, collecting, and drying to obtain valinomycin.
2. A method for separating and purifying valinomycin according to claim 1, characterized in that: (S.1) The organic solvent used for the concentration and purification is selected from one or more of methanol and ethanol.
3. A method for separating and purifying valinomycin according to claim 1, characterized in that: (S.2) The demulsification is carried out by washing with saturated sodium chloride water or by centrifugal demulsification.
4. A method for separating and purifying valinomycin as claimed in claim 1, characterized in that: (S.3) The eluent is a mixture of petroleum ether and acetone.
5. A method for separating and purifying valinomycin as claimed in claim 4, characterized in that: The eluent ratio in (S.3) is petroleum ether:acetone = 100:(0-20).
6. The method for separating and purifying valinomycin according to claim 5, characterized in that: The eluent volume is 0.5-2 BV.
7. The method for separating and purifying valinomycin according to claim 1, characterized in that: The gradient elution described in (S.3) yields 7 components with increasing polarity.
8. The method for separating and purifying valinomycin according to claim 7, characterized in that: (S.4) Concentrating the three components with greater polarity under reduced pressure.
9. The method for separating and purifying valinomycin according to claim 7, characterized in that: (S.4) The organic solvent used is one or more of methanol, ethanol, and n-butyl ether.
10. The method for separating and purifying valinomycin according to claim 1, characterized in that: (S.4) The crystallization process adopts 50°C water bath heating and gradient cooling to obtain high-purity valinomycin.
